HLA-DRβ5 Antibody (4D12): sc-53889

HLA-DRβ5 Antibody (4D12) is a mouse monoclonal IgG1 kappa light chain antibody that detects the HLA-DR beta 5 protein of human origin by western blotting (WB) and immunoprecipitation (IP). Anti-HLA-DR beta 5 antibody (4D12) is available as the non-conjugated isotype antibody. HLA-DR beta 5 protein plays a crucial role in immune response by forming part of the major histocompatibility complex (MHC) class II molecules, which are essential for presenting processed antigens to CD4+ T helper cells. This interaction is vital for T cell activation and subsequent orchestration of adaptive immune responses. HLA-DR beta 5 functioning is particularly important in autoimmune diseases, as variations in expression or function can influence susceptibility to conditions such as rheumatoid arthritis. HLA-DR beta 5 protein is located primarily in endosomal and lysosomal compartments, as well as on B cell surfaces, where HLA-DR beta 5 participates in exogenous peptide presentation. Peptide binding regulation to HLA-DR beta 5 is facilitated by other MHC molecules, such as HLA-DM and HLA-DO, which ensure optimal antigen-binding groove configuration for peptide exchange. Understanding HLA-DR beta 5 dynamics and interactions is essential for developing targeted therapies and improving immune system knowledge.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

HLA-DRβ5 Antibody (4D12) References:

1. HLA-DMA and HLA-DMB alleles in German patients with type 1 diabetes mellitus.  |  Siegmund, T., et al. 1999. Tissue Antigens. 54: 291-4. PMID: 10519369
2. Functional HLA-DM on the surface of B cells and immature dendritic cells.  |  Arndt, SO., et al. 2000. EMBO J. 19: 1241-51. PMID: 10716924
3. Functional characterization of a lysosomal sorting motif in the cytoplasmic tail of HLA-DObeta.  |  Brunet, A., et al. 2000. J Biol Chem. 275: 37062-71. PMID: 10964920
4. The down-regulation of HLA-DM gene expression in rheumatoid arthritis is not related to their promoter polymorphism.  |  Louis-Plence, P., et al. 2000. J Immunol. 165: 4861-9. PMID: 11046010
5. Determination of the HLA-DM interaction site on HLA-DR molecules.  |  Doebele, RC., et al. 2000. Immunity. 13: 517-27. PMID: 11070170
6. Monoclonal antibodies against human leucocyte antigens. I. Antibodies against beta-2-microglobulin, immunoglobulin kappa light chains, HLA-DR-like antigens, T8 antigen, T1 antigen, a monocyte antigen, and a pan-leucocyte antigen.  |  Horejsí, V., et al. 1986. Folia Biol (Praha). 32: 12-25. PMID: 2422063
7. Characterization of seven new monoclonal antibodies against human DR, DR + DP and DQ1 + DQ3 antigens.  |  Horejsí, V., et al. 1986. Tissue Antigens. 28: 288-97. PMID: 2435017
8. Description of monoclonal antibody defining an HLA allotypic determinant that includes specificities within the B5 cross-reacting group.  |  Haynes, BF., et al. 1982. Hum Immunol. 4: 273-85. PMID: 6181035
9. A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules.  |  Kropshofer, H., et al. 1998. EMBO J. 17: 2971-81. PMID: 9606180

The preferred HLA-DP antibody is HLA-DP Antibody (G-9): sc-390694.